Pneumocystis jiroveci pneumonia mimicking gefitinib-lnduced lung injury in a patient with lung cancer

Minehiko Inomata; Ryuji Hayashi; Chihiro Taka; Seisuke Okazawa; Toru Yamada; Toshiro Miwa; Tatsuhiko Kashii; Shoko Matsui; Kazuyuki Tobe

Pneumocystis jiroveci pneumonia mimicking gefitinib-lnduced lung injury in a patient with lung cancer

Minehiko Inomata^*, Ryuji Hayashi, Chihiro Taka, Seisuke Okazawa, Toru Yamada, Toshiro Miwa, Tatsuhiko Kashii, Shoko Matsui, Kazuyuki Tobe

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Abstract

A 76-year-old man was diagnosed with advanced lung adenocarcinoma and received treatment with gefitinib. In addition, prednisolone was started for severe appetite loss. However, the patient complained of dyspnea and a chest CT revealed bilateral ground glass opacity. Gefitinib-induced lung injury was suspected, and the drug was discontinued. However, it was found that the serum level of beta-D glucan was higher than 300 pg/ml. After further detailed investigation, a diagnosis of Pneumocystis jiroveci pneumonia (PCP) was made. Treatment with trimethoprim-sulphamethoxazole was started and the abnormal shadows and dyspnea disappeared. Treatment with gefitinib could be resumed without any adverse effect. The present case highlights the need for appropriate investigation and diagnosis in patients developing abnormal shadows on chest imaging during treatment with gefitinib.

Original language	English
Pages (from-to)	955-960
Number of pages	6
Journal	Japanese Journal of Chest Diseases
Volume	70
Issue number	9
State	Published - 2011/09/20

Keywords

Drug-induced lung injury
Gefitinib
Pneumocystis jiroveci pneumonia

ASJC Scopus subject areas

Pulmonary and Respiratory Medicine

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@article{7f1716ccd50c4bfbbfa7857b7e2472eb,

title = "Pneumocystis jiroveci pneumonia mimicking gefitinib-lnduced lung injury in a patient with lung cancer",

abstract = "A 76-year-old man was diagnosed with advanced lung adenocarcinoma and received treatment with gefitinib. In addition, prednisolone was started for severe appetite loss. However, the patient complained of dyspnea and a chest CT revealed bilateral ground glass opacity. Gefitinib-induced lung injury was suspected, and the drug was discontinued. However, it was found that the serum level of beta-D glucan was higher than 300 pg/ml. After further detailed investigation, a diagnosis of Pneumocystis jiroveci pneumonia (PCP) was made. Treatment with trimethoprim-sulphamethoxazole was started and the abnormal shadows and dyspnea disappeared. Treatment with gefitinib could be resumed without any adverse effect. The present case highlights the need for appropriate investigation and diagnosis in patients developing abnormal shadows on chest imaging during treatment with gefitinib.",

keywords = "Drug-induced lung injury, Gefitinib, Pneumocystis jiroveci pneumonia",

author = "Minehiko Inomata and Ryuji Hayashi and Chihiro Taka and Seisuke Okazawa and Toru Yamada and Toshiro Miwa and Tatsuhiko Kashii and Shoko Matsui and Kazuyuki Tobe",

year = "2011",

month = sep,

day = "20",

language = "英語",

volume = "70",

pages = "955--960",

journal = "Japanese Journal of Chest Diseases",

issn = "0385-3667",

publisher = "Kokuseido Publishing Co. Ltd",

number = "9",

}

TY - JOUR

T1 - Pneumocystis jiroveci pneumonia mimicking gefitinib-lnduced lung injury in a patient with lung cancer

AU - Inomata, Minehiko

AU - Hayashi, Ryuji

AU - Taka, Chihiro

AU - Okazawa, Seisuke

AU - Yamada, Toru

AU - Miwa, Toshiro

AU - Kashii, Tatsuhiko

AU - Matsui, Shoko

AU - Tobe, Kazuyuki

PY - 2011/9/20

Y1 - 2011/9/20

N2 - A 76-year-old man was diagnosed with advanced lung adenocarcinoma and received treatment with gefitinib. In addition, prednisolone was started for severe appetite loss. However, the patient complained of dyspnea and a chest CT revealed bilateral ground glass opacity. Gefitinib-induced lung injury was suspected, and the drug was discontinued. However, it was found that the serum level of beta-D glucan was higher than 300 pg/ml. After further detailed investigation, a diagnosis of Pneumocystis jiroveci pneumonia (PCP) was made. Treatment with trimethoprim-sulphamethoxazole was started and the abnormal shadows and dyspnea disappeared. Treatment with gefitinib could be resumed without any adverse effect. The present case highlights the need for appropriate investigation and diagnosis in patients developing abnormal shadows on chest imaging during treatment with gefitinib.

AB - A 76-year-old man was diagnosed with advanced lung adenocarcinoma and received treatment with gefitinib. In addition, prednisolone was started for severe appetite loss. However, the patient complained of dyspnea and a chest CT revealed bilateral ground glass opacity. Gefitinib-induced lung injury was suspected, and the drug was discontinued. However, it was found that the serum level of beta-D glucan was higher than 300 pg/ml. After further detailed investigation, a diagnosis of Pneumocystis jiroveci pneumonia (PCP) was made. Treatment with trimethoprim-sulphamethoxazole was started and the abnormal shadows and dyspnea disappeared. Treatment with gefitinib could be resumed without any adverse effect. The present case highlights the need for appropriate investigation and diagnosis in patients developing abnormal shadows on chest imaging during treatment with gefitinib.

KW - Drug-induced lung injury

KW - Gefitinib

KW - Pneumocystis jiroveci pneumonia

UR - http://www.scopus.com/inward/record.url?scp=80053007209&partnerID=8YFLogxK

M3 - 学術論文

AN - SCOPUS:80053007209

SN - 0385-3667

VL - 70

SP - 955

EP - 960

JO - Japanese Journal of Chest Diseases

JF - Japanese Journal of Chest Diseases

IS - 9

ER -

Pneumocystis jiroveci pneumonia mimicking gefitinib-lnduced lung injury in a patient with lung cancer

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Fingerprint

Cite this